



Preventing the development of asthma: stopping the allergic march

Michelle C. Maciag and Wanda Phipatanakul

Purpose of review

To describe important precipitants of asthma and allergic disease, to highlight the links between these triggers and modifications within the immune system, and to examine innovative research regarding asthma prevention with focus on attenuating the atopic march.

Recent findings

Allergen avoidance, allergen immunotherapy, IgE antagonists, prevention and treatment of respiratory infections, as well as management of gastrointestinal and respiratory dysbiosis have been considered as strategies in asthma prevention. Antenatal vitamin D supplementation in expectant mothers and aggressive control of atopic dermatitis to prevent the development of other allergic conditions were carefully studied as well.

Summary

Asthma is a major cause of morbidity and lost productivity. Despite the tremendous burden of this disease, the scientific community is still struggling to find an effective means of prevention. The contribution of genetics to the development of atopy cannot be altered, but environmental changes as well as pharmacotherapy have been studied as modifiable risk factors. Many trials to date have been effective only for subjects with certain characteristics. This is likely because asthma is a heterogeneous condition, with a variety of triggers and clinical phenotypes. Thus far, a universally effective prevention strategy has eluded us. However, if an intervention can be found to prevent asthma and the allergic march, it will greatly improve quality of life for millions of sufferers and decrease healthcare expenditures.

Keywords

asthma, atopy, immunotherapy, prevention, sensitization

INTRODUCTION

Asthma affects approximately 300 million people globally, and represents the most common non-communicable disease. It carries a disproportionately high impact on children, and nearly 6 billion dollars are spent annually due to pediatric asthma alone [1]. Its impact is growing exponentially – it has been suggested that there may be an additional 100 million people suffering from asthma by 2025 [2]. The ‘atopic march’ refers to IgE-mediated allergic progression beginning with atopic dermatitis and food allergy in infancy, followed by aeroallergen sensitization in the preschool age, culminating in the development of allergic rhinitis and chronic asthma [3]. Preventing the inception of the allergic march, as well as halting its advance, is pivotal in asthma prevention. Aggressive therapies in infants with atopic dermatitis [4,5], global blocking of allergic inflammation with daily inhaled steroids [6], the role of allergic sensitization [7,8],

immunotherapy [9–15,16^{••}], respiratory infections [17–19,20^{••}], and dietary interventions [21,22[•]] have been evaluated in asthma and atopy prevention. Biologic therapy for susceptible toddlers [23], and modulation of the respiratory microbiome through killed bacterial lysates are being investigated [24–26]. The influence of environmental factors, such as pollution, in asthma pathogenesis is well established [27]. Our ability to intervene upon these contributing factors can alter the course of the disease and is the focus of ongoing investigation.

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Wanda Phipatanakul, MD, MS, Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Tel: +1 617 355 6117; e-mail: Wanda.Phipatanakul@childrens.harvard.edu

Curr Opin Allergy Clin Immunol 2019, 19:161–168

DOI:10.1097/ACI.0000000000000501

KEY POINTS

- Vitamin D and probiotics may be helpful in preventing allergic disorders, but currently their benefit seems to be limited to certain populations and at specific times. More research regarding their use for prevention of atopy in the general population is needed, with focus on prospective studies with long-term follow-up, which is lacking in the current literature regarding these supplements.
- Allergic sensitization plays an integral role in asthma pathogenesis.
- There is a synergistic effect between allergic sensitization and viral infection in the development of asthma, and IgE likely plays a causal role in regulating asthma severity.
- Prevention of allergic sensitization and improved antiviral immunity during the toddler years, a critical period for immune as well as pulmonary development, may be helpful in preventing asthma. Omalizumab may be helpful in this capacity and is being studied for asthma prevention.

EARLY CONTROL OF ATOPIC DERMATITIS FOR ATOPY PREVENTION

As the atopic march often begins with atopic dermatitis, children with this condition have been targeted in prevention studies. The Early Treatment of the Atopic Child study was a double-blinded, parallel group, randomized controlled trial of cetirizine administered twice daily over 18 months to children with atopic dermatitis, with 18 months of further follow-up. Overall the intervention group did not have a lower prevalence of asthma when compared with the placebo group; however, a specific subgroup of children, those sensitized to house dust mite (HDM) and/or grass pollen, were less likely to develop asthma while taking cetirizine. The preventive effect continued through the 18-month follow-up period for those sensitized to grass [5].

Another study considered whether intensive pharmacotherapy for control of atopic dermatitis could limit progression of the atopic march. The Study of the Atopic March was a prospective, randomized, double-blind, placebo-controlled, longitudinal study evaluating the use of pimecrolimus, a topical calcineurin inhibitor, in infants aged 3–18 months with atopic dermatitis. Children were followed for 3 years or longer, but there was no difference between intervention and control groups in the prevalence of asthma, or other allergic conditions [4].

INHALED CORTICOSTEROIDS FOR ASTHMA PREVENTION

In the Prevention of Early Asthma in Kids cohort, preschoolers at risk of asthma were also found to have a high rate of aeroallergen sensitization [28]. Children determined to be at risk of asthma through the asthma predictive index [29] were then treated preemptively with 2 years of inhaled corticosteroids and followed 1 year after. While the intervention improved asthma control during treatment, it did not decrease burden or alter the progression of the disease after the therapy was stopped [6].

VITAMIN D

The intrauterine period may represent a critical window in the development of atopy and asthma. Data suggests that higher in utero 25-hydroxy-vitamin D confers protection against the development of asthma. A total of 581 pregnant women were randomized to high-dose vitamin D (either 2400 or 4000 IU daily) or placebo. There was a 25% reduced risk of asthma in the offspring of the treated mothers at 0–3 years [30]. Mechanistically, the importance of vitamin D makes sense, as suboptimal levels of vitamin D may lead to impairment of various immune functions involved in asthma and allergic disorders [31]. However, most wheezing that occurs prior to age 3 is attributable to transient viral infection and not persistent asthma. Thus, long-term follow-up of these studies is essential to determine if this therapy prevents the development of chronic asthma [32].

Traffic pollution, in combination with allergen exposure, synergistically precipitates asthma exacerbations [33,34]. Vitamin D may attenuate airway inflammation in the setting of pollution [22[¶]]. Exposure of infants to the 1952 Great Smog of London increased asthma rates by about 20% [27]. Bolcas and Brandt [22[¶]] reported that vitamin D confers protection against asthma development in the setting of exposure to traffic related air pollution. Vitamin D replacement did not reverse established asthma, but maintenance of normal vitamin D status in childhood significantly mitigated the development of airway hyperresponsiveness in allergic asthma that was worsened by diesel exhaust. It is suggested that vitamin D reduces pulmonary Th2/TH17 cells, which portend the development of severe asthma.

MODIFICATION OF THE MICROBIOME

The bacterial milieu has been studied in asthma pathogenesis, and modifying the microbiome is

being targeted in asthma and atopy prevention. Broncho-Vaxom is an oral immunomodulator containing a bacterial lysate of pathogenic respiratory bacteria which can stimulate immune defenses and is used to prevent recurrent infections. A recent meta-analysis involving 4851 pediatric patients, confirmed that its administration significantly reduced the frequency of respiratory infection [35].

However, the data behind the use of bacterial lysates for atopy prevention varies. In one mouse model of asthma, oral administration of Broncho-Vaxom attenuated airway inflammation as measured by airway wall thickness, luminal stenosis, mucus plugging, and eosinophilic infiltration [25]. Conversely, in another murine model, Broncho-Vaxom did not reduce pulmonary eosinophilic response, or improve lung resistance, but did decrease IL-5 and IL-13 in bronchoalveolar lavage fluid [26]. A clinical trial, Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX), NCT02148796, is currently underway, to assess the efficacy of killed bacterial lysates in asthma prevention [36].

PROBIOTICS

Probiotics have been evaluated in the prevention of atopy. Strains of lactobacilli and bifidobacteria are the most commonly employed for the prevention of allergic disease [37]. A large meta-analysis of 2403 studies showed that probiotics may prevent atopic dermatitis, but not prevent other allergic conditions [38]. However, another randomized, prospective, double-blinded controlled trial did not show that probiotics decreased atopic dermatitis or asthma risk at age 2 [39]. The different outcomes between these two analyses highlight the heterogeneity of this disease, as genetic and environmental factors modulate both the disease itself, as well as attempted interventions.

AVOIDANCE OF ALLERGIC SENSITIZATION

Allergic sensitization plays an integral role in atopy pathogenesis and progression, especially with regards to asthma [40]. Recent population level studies in the US have indicated that almost half of the US population is sensitized to aeroallergens and that exposure to multiple allergens in homes is common [41]. A study from the 1960s showed that the presence of allergic sensitization and allergic rhinitis significantly decreased the likelihood that a child would outgrow his asthma by age 16. This indicates that allergic sensitization is a critical step in asthma development [42]. In a 2017 study, 127

infants hospitalized or seen in the ED for first severe wheeze, were followed to determine asthma prevalence at 8 years. The 17% who were sensitized to allergens at the time of study entry (median age 11 months) had a 12 times higher risk of developing atopic asthma by age 8 than their nonsensitized counterparts [20¹¹].

Information from the Childhood Origins of Asthma (COAST) cohort informs the relationship between allergen exposure and asthma development. Allergen-specific IgE was measured at four intervals between 1 and 9 years of age, in a population at high-risk for asthma development. Sensitization to specific perennial allergens, like cat and dog, was highly associated with asthma risk. Interestingly, dog exposure at birth was associated with a reduced risk of asthma, irrespective of sensitization status [40]. Specific gene–environment interactions such as the effect of pet exposure on those with a high-risk variant in the chromosome 17q21 locus, may modify the relation between pet exposure and asthma in at-risk individuals [43]. Recent analyses suggest that clusters of exposure combined with specific sensitization can augment asthma risk, highlighting the complexity of this progression [44,45].

Given the critical role that allergic sensitization plays in the development of atopy, allergen avoidance was studied as a means of prevention. In the Isle of Wight prevention study, infants at high risk of atopy were randomized to an intervention group that included breastmilk by a mother on a low allergen diet or hydrolyzed formula, with reduced exposure to HDM or to a control group without intervention. A significant decrease in asthma, atopic dermatitis, rhinitis and atopy was seen in the prevention group [7]. At age 18, asthma was still less prevalent in those who had received the intervention. However, the prevalence of atopy and allergic sensitization had equalized [8]. While this study showed that allergen avoidance had a preventive effect, other studies have been equivocal or shown an increase in atopy (Table 1). Allergenic and microbial exposures are complex [49], making the practical implementation of these avoidance measures difficult.

ALLERGEN IMMUNOTHERAPY

Aside from allergen avoidance for the prevention of asthma and atopy, targeting allergic sensitization through immunotherapy, has been studied in the prevention of asthma and atopy in several controlled trials (Table 2) [9,12,13,15,16¹¹,51]. A Cochrane analysis concluded that immunotherapy improves asthma symptoms, reduces bronchial

Table 1. Select studies evaluating the association between allergic sensitization and asthma development

References	Population	Study design	Intervention	Asthma-related outcome	Other clinically relevant outcomes
Cullinan <i>et al.</i> [46]	625 children followed from birth to age 5.5 years	Prospective cohort study	Der p 1 and Fel d 1 allergens measured in homes at 8 weeks of life. Annual interview regarding wheeze. SPT completed at 5.5 years.	7% had atopic wheeze. Risk of asthma rose at low exposure level and then was attenuated thereafter.	10% sensitized to HDM or cat. No relation between allergen exposure and sensitization or wheeze found.
Marks <i>et al.</i> [47]	616 children with family history of asthma were randomized antenatally and followed through the first 5 years of life	Prospective RCT	Intervention 1: HDM avoidance vs control Intervention 2: Dietary modification vs control. Assessed for asthma and eczema and had skin prick tests for atopy at age 5.	No significant difference in the prevalence of asthma in the HDM avoidance group.	HDM avoidance resulted in a decrease in HDM in the child's bed. No significant difference in the prevalence of eczema, or atopy.
Arshad <i>et al.</i> [7]	120 infants recruited prenatally from atopic families Study focused on limiting food and HDM exposure	Prospective single-blind RCT	Intervention ($n = 58$): Infant Breast-fed by mother on low allergen diet or given extensively hydrolyzed formula. HDM exposure reduced by acaricide and mattress covers. Control ($n = 62$): Standard advice	At age 8, statistically significant decrease in asthma.	At age 8, statistically significant decrease in allergic sensitization to foods as well as HDM, allergic rhinitis, atopic dermatitis and atopy in the intervention group.
Scott <i>et al.</i> [8]	120 infants recruited prenatally from atopic families Study focused on limiting food and HDM exposure	Prospective single-blind RCT	Intervention ($n = 56$): Infant breast-fed by mother on low allergen diet, or given extensively hydrolyzed formula. HDM exposure reduced by acaricide and mattress covers. Control ($n = 58$): Standard advice	At age 18, statistically significant decrease in asthma.	At age 18, no difference in allergic sensitization to foods as well as HDM, or atopy in the intervention group.
Stoltz <i>et al.</i> [40]	High-risk children for development of asthma and allergy enrolled in the COAST study	Prospective longitudinal cohort study	Specific IgE measured at 1, 3, 6, and 9 years. Current asthma and allergic rhinitis diagnosed at 6 and 8 years.	Sensitization to cat and dog associated with increased asthma risk. Sensitization to perennial versus seasonal allergens also associated with asthma risk. Dog exposure at birth associated with decreased asthma risk, regardless of sensitization.	Sensitization to seasonal allergens more associated with rhinitis risk.
Belgrave <i>et al.</i> [48]	1046 patients from ages 5–24 from MAAS and ALSPAC cohorts followed with spirometry to ascertain trajectories of FEV1	Prospective longitudinal cohort study	Factors influencing FEV1 were studied in these two cohorts.	Participants with recurrent severe wheeze exacerbation by age 3 years ($P = 0.048$) and allergic sensitization at 3 ($P = 0.017$) had increased likelihood of belonging to the subgroup of persistently low FEV1.	

IT, immunotherapy; SLIT, sublingual immunotherapy; SCIT, subcutaneous immunotherapy; SPT, skin prick test; RCT, randomized controlled trial; HDM, house dust mite; FEV1, forced expiratory volume in one second; MAAS, Manchester Asthma and Allergy Study; ALSPAC, Avon Longitudinal Study of Parents and Children.

Table 2. Selected studies evaluating the role of immunotherapy in the prevention of atopy and asthma

References	Population	Study design	Intervention	Asthma-related outcome	Other clinically relevant outcomes
Johnstone and Crump [50]	200 children sensitized to inhalants, age 0–15, with perennial bronchial asthma	Prospective randomized controlled, double-blinded	Each therapy given for 4 years. Control (n = 42): SCIT with buffered saline. Intervention 1 (n = 49) SCIT 1/10 000 000 weight by volume to all sensitized inhalants based on SPT. Intervention 2 (n = 39): SCIT 1/5000 dilution of all sensitized antigens < LBREAK / >—Intervention 3 (n = 43) highest tolerated dose of SCIT, up to 1/250 dilution.	64% of the control group displayed wheezing on exertion, while only 9% of those receiving the highest tolerated dose of immunotherapy displayed wheeze with exertion.	None of the children in intervention groups 2 or 3 developed new sensitizations while on immunotherapy.
Johnstone and Dutton [42]	210 children with perennial allergic rhinitis and asthma assessed at age 16	Prospective randomized placebo-controlled study	The same interventions as above.	22% of placebo-treated children were symptom free, while 72% of treated children were symptom free (66% of the 1/5000 group, and 78% of the highest tolerated dose group were symptom free.)	Only 12 of 73 children had asthma develop prior to allergic rhinitis. Presence of allergic rhinitis during childhood significantly lessened the likelihood that a child in this study would outgrow asthma by age 16.
Novembre <i>et al.</i> [15]	113 children aged 5–14 years with allergic rhinitis and grass allergy, but no prior signs of asthma	Prospective randomized open controlled study	Intervention (n = 54): Treated with grass SLIT for 3 years Control (n = 59): Standard pharmacotherapy.	There was a four-fold increased rate of asthma development in the children allergic to grass and not treated with IT.	Treated children had reduced symptoms and used less medication in the second and third years.
Jacobsen <i>et al.</i> [9]	147 subjects, aged 16–25 years, with grass ± birch pollen allergy	Prospective open, partially RCT	Intervention (n = 64): SCIT with standardized birch ± grass pollen extracts for 3 years. Control (n = 53): Standard medical therapy for allergic rhinitis.	10 years later, those treated with SCIT had a statistically significant lower rate of asthma than those in the control group	Allergic rhinitis in SCIT group improved significantly more than pharmacotherapy group
Marogna <i>et al.</i> [13]	78 adult patients, aged 18–65, all mono-sensitized to HDM	Prospective open, RCT	Intervention 1 (n = 19): SLIT to HDM for 3 years Intervention 2 (n = 21): SLIT to HDM for 4 years Intervention 3 (n = 17): SLIT to HDM for 5 years Control (n = 21): pharmacotherapy alone.		In intervention groups, new sensitizations developed in only 21%. In intervention group 1, benefit persisted for 7 years. Intervention groups 2 and 3 had benefit for 8 years. No change in control group, over 15 years, new sensitizations developed in 100%.
Zolkipli <i>et al.</i> [51]	111 infants < 1-year-old at high risk of atopy, but not yet sensitized	Prospective, double blind, RCT	Intervention (n = 57): HDM extract given orally twice daily for 12 months Control (n = 54): Placebo administered orally twice daily for 12 months.	SLIT had no significant preventive effect on wheeze.	Sensitization to any common allergen 25.5% in control group and only 16% in the intervention group. No effect on atopic dermatitis, or food allergy.
Marogna <i>et al.</i> [12]	142 patients (age 8–57) with allergic rhinitis, mono-sensitized to HDM	Prospective open, nonrandomized, controlled	Intervention 1 (n = 41): Adjuvanted SLIT (bacterial wall derived adjuvants, that engage TLRs) Intervention 2 (n = 43): Standard SLIT Control (n = 40): Pharmacotherapy only.	Patients in the control group had a decline in FEV1 over the 5 years of the study, while those treated with IT had stable FEV1.	After 5 years of treatment, 58% of the control group developed new sensitizations, while 13.2% in the standard SLIT group did and only 8.1% in the adjuvanted group did. Patients treated with SLIT used less medications.
Valovirta <i>et al.</i> [16▪▪]	812 children, aged 5–12 years with allergic rhinitis caused by grass pollen, but no medical history or signs of asthma	Prospective, randomized, double-blind, placebo-controlled trial	Intervention (n = 398): 3 years of treatment with grass SLIT Control (n = 414): Placebo tablets.	Treatment with grass SLIT in sensitized individuals reduced the risk of experiencing asthma symptoms or using asthma medications at the end of the trial, which was a total of 5 years. Did not significantly prevent asthma.	Use of allergic rhinitis pharmacotherapy was significantly less in the intervention group. Total IgE, grass pollen specific IgE and SPT reactivity were reduced in the intervention group.

IT, immunotherapy; SLIT, sublingual immunotherapy; SCIT, subcutaneous immunotherapy; SPT, Skin Prick Test; HDM, House dust mite; FEV1, forced expiratory volume in 1 second.

hyperreactivity, and minimizes the need for asthma medications [50]. The role of immunotherapy in prevention of new sensitization as well as in mitigation of asthma symptoms has been appreciated since the 1960s [52]. Immunotherapy can improve the likelihood that a known asthmatic will outgrow his asthma [42]. Several randomized controlled trials have demonstrated that immunotherapy minimizes new allergic sensitization in individuals already sensitized to other allergens, but its effect on asthma prevention has varied [13,15,51].

In a prospective, randomized controlled study, Jacobsen *et al.* [9] evaluated 3 years of subcutaneous immunotherapy (SCIT) in children with seasonal allergic rhinitis and found that at 10 years, allergic rhinoconjunctivitis along with reported asthma rates were significantly lower in the SCIT group, as compared with those who did not receive immunotherapy. The study had several limitations: it was not blinded, and while reported diagnoses of asthma were statistically significant, bronchial hyperresponsiveness as measured by methacholine challenge was not significantly different between the two groups [9].

Sublingual immunotherapy (SLIT) has been extensively studied for asthma and atopy prevention [12,13,15,16²²]. In one prospective, randomized controlled, proof-of-concept study in infants at high risk of atopy, the intervention group was treated with HDM oral immunotherapy, twice daily for 1 year, while the control was treated with placebo. While the study confirmed decreased sensitization to common allergens in the intervention group, there was no effect on the development of atopic dermatitis, food allergy, or wheeze [51]. Another open, randomized controlled trial was more promising. This study involved 113 children between ages 5 and 14 with allergic rhinitis who were sensitized to grass. The intervention arm received 3 years of grass SLIT and the control group received standard medical therapy. The control group had a four-fold increased rate of asthma as compared with the group who received immunotherapy, suggesting that immunotherapy may have a protective effect against asthma development [15].

In patients sensitized to HDM who were treated with SLIT, spirometry and bronchoprovocation via methacholine were studied and confirmed that SLIT, over a 5-year period, had a significant protective effect on pulmonary function, as compared to a control group of sensitized individuals who did not receive immunotherapy [12]. Furthermore, a recent metaanalysis evaluated allergen immunotherapy in those with allergic rhinitis and found a statistically significant reduction in the development of asthma

in the 2 years following completion of immunotherapy [11]. It is unclear if this benefit is pervasive.

The mixed results from these trials indicate that immunotherapy may be helpful in the prevention of asthma and atopy, but more research is needed to help determine which patients will benefit, and for how long. Immunotherapy interferes with the pathophysiology that mediates allergic and asthmatic disease, and can potentially impact the progression of atopy over the long-term. One proposed mechanism is that immunotherapy induces specific IgG4 which mitigates allergic inflammation with resultant reduction in late-phase airway hyperreactivity [10].

PREVENTION OF RESPIRATORY INFECTIONS

There is robust data that allergic sensitization and viral infection interact synergistically in the pathogenesis of asthma. Allergic sensitization, particularly to HDM and mouse, combined with early-life rhinovirus infection compounds the risk of developing asthma and also increases asthma severity. This suggests that IgE may play a significant role in modifying asthma severity. While genes underlie a predisposition to sensitization, exposure to allergens, respiratory infections, and pollution may modify asthma severity seen among individuals [19].

More than 80% of asthma exacerbations are triggered by respiratory viral infections, and two-thirds of these are attributable to rhinovirus, which also increases asthma severity [19]. It is postulated that rhinovirus disrupts the airway epithelium, upregulates IL-25 and IL-33, and catalyzes type 2 airway inflammation and remodeling [18²²]. Limiting the pulmonary inflammation ignited by rhinovirus is a possible intervention point in stymying the progression of transient wheeze to asthma. Omalizumab may be helpful in this regard [53].

OMALIZUMAB FOR ATOPY AND ASTHMA PREVENTION

Omalizumab (Anti-IgE) has been shown to significantly decrease asthma related symptom days, fall and spring exacerbations, hospitalizations, and need for inhaled corticosteroids [54]. In the Preventive Omalizumab or Step-up Therapy for Fall Exacerbation (PROSE) study, treatment with omalizumab also decreased the risk and duration of rhinovirus infections, and minimized viral shedding. By antagonizing IgE, omalizumab may limit both the allergic and virally induced airway inflammation that underscores asthma pathogenesis and may play an

advantageous role in prevention [54]. Mechanistically, blocking IgE may inhibit the allergic sensitization that mediates asthma pathogenesis. Additionally, the cross-linking of IgE may restore virus induced IFN- α responses, which are often lacking in asthmatic patients [55].

Given omalizumab's benefit in asthma and its underlying mechanism of blocking IgE, as well as alleviating the burden of rhinovirus, omalizumab is under consideration as a therapy for asthma prevention and disease modification. Preschool is considered a 'critical period' in the maturation of the immune and pulmonary systems. The Preventing Asthma in High Risk Kids study (NCT02570984) is currently underway to determine whether 2 years of omalizumab therapy in predisposed preschoolers can prevent asthma development [23].

CONCLUSION

The concept of the 'allergic march' as a progression has recently been called into question, as more than 90% of children do not follow the typical trajectory. However, the contribution of atopic sensitization to these disorders is paramount [46]. Furthermore, asthma is a heterogeneous entity, influenced by both genetic and environmental factors. These make finding a 'one-size fits all' prevention strategy a challenging task. Tang *et al.* [45] recently reported on three distinct trajectories of asthma, one higher-risk, atopic cluster, and two lower risk clusters more prone to transient wheeze, including one nonatopic subgroup and one group susceptible to nonatopic and atopic wheeze. Each cohort may require different strategies for prevention. In the future, genetic variations among susceptible individuals with distinct asthma phenotypes, may help target prevention strategies in a more precise manner. Currently, we know that allergic sensitization combined with early life viral infections synergistically regulate asthma development and severity [19].

Acknowledgements

None.

Financial support and sponsorship

M.C.M. is funded under T32AI007512. W.P. is funded under K-24 AI106822, U01 AI110397, U01AI126614 and the Allergy Asthma Awareness Initiative.

Conflicts of interest

W.P. has served as a consultant/advisor within the last 3 years <\$5000 annually for Novartis, Genentech, Regeneron, GSK, Teva, Astra Zeneca.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Gur M, Hakim F, Bentur L. Better understanding of childhood asthma, towards primary prevention – are we there yet? Consideration of pertinent literature. *F1000Res* 2017; 6:2152.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 2004; 59:469–478.
3. Rhodes HL, Sporik R, Thomas P, *et al.* Early life risk factors for adult asthma: a birth cohort study of subjects at risk. *J Allergy Clin Immunol* 2001; 108:720–725.
4. Schneider L, Hanifin J, Boguniewicz M, *et al.* Study of the atopic march: development of atopic comorbidities. *Pediatr Dermatol* 2016; 33:388–398.
5. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. *J Allergy Clin Immunol* 2001; 108:929–937.
6. Guilbert TW, Morgan WJ, Zeiger RS, *et al.* Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006; 354:1985–1997.
7. Arshad SH, Bateman B, Sadeghnejad A, *et al.* Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. *J Allergy Clin Immunol* 2007; 119:307–313.
8. Scott M, Roberts G, Kurukulaaratchy RJ, *et al.* Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. *Thorax* 2012; 67:1046–1051.
9. Jacobsen L, Niggemann B, Dreborg S, *et al.* Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy* 2007; 62:943–948.
10. Jacobsen L, Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit – the centenary of allergen specific subcutaneous immunotherapy. *Clin Transl Allergy* 2012; 2:8.
11. Kristiansen M, Dhimi S, Netuveli G, *et al.* Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. *Pediatr Allergy Immunol* 2017; 28:18–29.
12. Marogna M, Massolo A, Passalacqua G. Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period. *World Allergy Organ J* 2017; 10:7.
13. Marogna M, Spadolini I, Massolo A, *et al.* Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. *J Allergy Clin Immunol* 2010; 126:969–975.
14. Martignago IIC, Ridolo E. Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence. *Clin Mol Allergy* 2017; 15; 13.
15. Novembre E, Galli E, Landi F, *et al.* Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2004; 114:851–857.
16. Valovirta E, Petersen TH, Piotrowska T, *et al.* Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. *J Allergy Clin Immunol* 2018; 141:529.e13–538.e13.
- A thoughtfully completed study evaluating SLIT for grass-sensitized patients in asthma prevention.
17. Beigelman A, Bacharier LB. Early-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease prevention. *Curr Opin Allergy Clin Immunol* 2016; 16:172–178.
18. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. *J Allergy Clin Immunol* 2017; 140:895–906.
- New evidence highlighting the role of airway inflammation caused by viruses in the pathogenesis of pediatric asthma.
19. Kantor DB, Stenquist N, McDonald MC, *et al.* Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. *J Allergy Clin Immunol* 2016; 138:1467.e9–1471.e9.
20. Lukkarinen M, Koistinen A, Turunen R, *et al.* Rhinovirus-induced first wheezing episode predicts atopic but not nonatopic asthma at school age. *J Allergy Clin Immunol* 2017; 140:988–995.
- Study evaluating the persistence of asthma in sensitized vs. nonsensitized children and confirming principles of the allergic march.
21. Yang H, Xun P, He K. Fish and fish oil intake in relation to risk of asthma: a systematic review and meta-analysis. *PLoS One* 2013; 8:e80048.
22. Bolcas PE, Brandt EB, Zhang Z, Vitamin D Supplementation attenuates asthma development following traffic-related particulate matter exposure. *J Allergy Clin Immunol* 2018; Epub ahead of print.
- Study highlighting the benefits of vitamin D supplementation in asthma worsened by pollution.

23. Humbert M, Busse W, Hanania NA. Controversies and opportunities in severe asthma. *Curr Opin Pulm Med* 2018; 24:83–93.
24. Koatz AM, Coe NA, Ciceran A, Alter AJ. Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. *Lung* 2016; 194:687–697.
25. Liu C, Huang R, Yao R, Yang A. The immunotherapeutic role of bacterial lysates in a mouse model of asthma. *Lung* 2017; 195:563–569.
26. Rodrigues A, Gualdi LP, de Souza RG, *et al*. Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model. *Allergol Immunopathol (Madr)* 2016; 44:504–511.
27. Bharadwaj P, Zivin JG, Mullins JT, Neidell M. Early-life exposure to the great smog of 1952 and the development of asthma. *Am J Respir Crit Care Med* 2016; 194:1475–1482.
28. Guilbert TW, Morgan WJ, Zeiger RS, *et al*. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. *J Allergy Clin Immunol* 2004; 114:1282–1287.
29. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000; 162(4 Pt 1):1403–1406.
30. Wolsk HM, Chawes BL, Litonjua AA, *et al*. Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled trials. *PLoS One* 2017; 12:e0186657.
31. Douros K, Boutopoulou B, Fouzas S, Loukou I. Asthma and allergy epidemic' and the role of vitamin D deficiency. *Adv Exp Med Biol* 2017; 996:169–183.
32. von Mutius E, Martinez FD. Inconclusive results of randomized trials of prenatal vitamin D for asthma prevention in offspring: curbing the enthusiasm. *JAMA* 2016; 315:347–348.
33. Brandt EB, Biagini Myers JM, Acciani TH, *et al*. Exposure to allergen and diesel exhaust particles potentiates secondary allergen-specific memory responses, promoting asthma susceptibility. *J Allergy Clin Immunol* 2015; 136:295.e7–303.e7.
34. Sheehan WJ, Gaffin JM, Peden DB, *et al*. Advances in environmental and occupational disorders in. *J Allergy Clin Immunol* 2017; 140:1683–1692.
35. Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. *Int Immunopharmacol* 2018; 54:198–209.
36. Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX) [Internet]. 2014 May 28. Available from: clinicaltrials.gov/ct2/show/NCT02148796. [Accessed 29 October 2018]
37. West CE, Jenmalm MC, Kozyrskyj AL, Prescott SL. Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward. *Expert Rev Clin Immunol* 2016; 12:625–639.
38. Cuello-Garcia CA, Brozek JL, Fiocchi A, *et al*. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin Immunol* 2015; 136:952–961.
39. Cabana MD, McKean M, Caughey AB, *et al*. Early probiotic supplementation for eczema and asthma prevention: a randomized controlled trial. *Pediatrics* 2017; 140:e20163006.
40. Stoltz DJ, Jackson DJ, Evans MD, *et al*. Specific patterns of allergic sensitization in early childhood and asthma and rhinitis risk. *Clin Exp Allergy* 2013; 43:233–241.
41. Gold DR, Adamkiewicz G, Arshad SH, *et al*. NIAID, NIEHS, NHLBI, and MCAN Workshop Report: the indoor environment and childhood asthma-implications for home environmental intervention in asthma prevention and management. *J Allergy Clin Immunol* 2017; 140:933–949.
42. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children – a 14-year study. *Pediatrics* 1968; 42:793–802.
43. Stokholm J, Chawes BL, Vissing N, *et al*. Cat exposure in early life decreases asthma risk from the 17q21 high-risk variant. *J Allergy Clin Immunol* 2018; 141:1598–1606.
44. Bacharier LB, Beigelman A, Calatroni A, *et al*. Longitudinal phenotypes of respiratory health in a high-risk urban birth cohort. *Am J Respir Crit Care Med* 2018; Epub ahead of print.
45. Tang HH, Teo SM, Belgrave DC, *et al*. Trajectories of childhood immune development and respiratory health relevant to asthma and allergy. *Elife* 2018; 7:pii: e35856.
46. Cullinan P, MacNeill SJ, Harris JM, *et al*. Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study. *Thorax* 2004; 59:855–861.
47. Marks GB, Mirshahi S, Kemp AS, *et al*. Prevention of asthma during the first 5 years of life: a randomized controlled trial. *J Allergy Clin Immunol* 2006; 118:53–61.
48. Belgrave DCM, Granell R, Turner SW, *et al*. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. *Lancet Respir Med* 2018; 6:526–534.
49. O'Connor GT, Lynch SV, Bloomberg GR, *et al*. Early-life home environment and risk of asthma among inner-city children. *J Allergy Clin Immunol* 2018; 141:1468–1475.
50. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. *Cochrane Database Syst Rev* 2010; (8):001186.
51. Zolkipli Z, Roberts G, Cornelius V, *et al*. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. *J Allergy Clin Immunol* 2015; 136:1541.e11–7.e11.
52. Johnstone DE, Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. *Pediatrics* 1961; 27:39–44.
53. Esquivel A, Busse WW, Calatroni A, *et al*. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. *Am J Respir Crit Care Med* 2017; 196:985–992.
54. Busse WW, Morgan WJ, Gergen PJ, *et al*. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med* 2011; 364:1005–1015.
55. Gill MA, Liu AH, Calatroni A, *et al*. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. *J Allergy Clin Immunol* 2018; 141:1735.e9–1743.e9.